Biogen Buyout Bet On Felzartamab: A Hidden Blockbuster In The Making?

Biogen has recently taken a notable step in reshaping its immunology and nephrology profile by entering into a definitive agreement with TJ Biopharma to acquire the latter’s exclusive rights to felzartamab in the Greater China region, thereby consolidating worldwide development and commercialization rights to the asset under one owner. The transaction follows Biogen’s earlier acquisition of HI-Bio in 2024, which gave it rights to felzartamab outside Greater China, and it comes at a time when management is increasingly emphasizing late-stage pipeline execution as a bridge to offset erosion in the legacy multiple sclerosis franchise. Under the agreement, TJ Biopharma is set to receive a $100 million upfront payment and could receive up to $750 million in commercial and sales milestones, alongside royalties on future net sales in Greater China.